Core Viewpoint - The AI Fund Hongyi Yuanfang State-Owned Enterprise Transformation Upgrade Mixed A (006369) reported a profit of 3.02 million yuan for the first half of 2025, with a net asset value growth rate of 9.19% [2] Fund Performance - As of September 3, the fund's unit net value was 1.606 yuan, with a one-year cumulative net value growth rate of 46.77%, ranking 251 out of 600 comparable funds [2][5] - The fund's three-month and six-month net value growth rates were 16.11% and 13.29%, ranking 383 out of 615 and 428 out of 615 respectively [5] - The fund's three-year net value growth rate was 1.96%, ranking 170 out of 340 [5] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 26.4 times, higher than the industry average of 25.34 times [10] - The weighted average price-to-book (P/B) ratio was about 2.42 times, compared to the industry average of 2.34 times [10] - The weighted average price-to-sales (P/S) ratio was around 2.87 times, exceeding the industry average of 2.09 times [10] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.1%, and the weighted average net profit growth rate was 0.22% [18] - The weighted annualized return on equity was 0.09% [18] Risk and Return Metrics - The fund's three-year Sharpe ratio was -0.1215, ranking 209 out of 319 comparable funds [27] - The maximum drawdown over the past three years was 36.54%, with the highest quarterly drawdown occurring in Q1 2022 at 22.6% [29] Fund Composition - As of June 30, 2025, the fund had a total scale of 31.9877 million yuan and held 678 investors, with individual investors accounting for 82.06% of the total holdings [33][36] - The top ten holdings included companies such as Beifang Huachuang, Guotai Haitong, and WuXi AppTec [42]

Core Viewpoint - The AI Fund Fidelity Enjoy Dividend Preferred Mixed A (020493) reported a profit of 7.5547 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.0873 yuan, and a net asset value growth rate of 10.19% during the same period [2]. Fund Performance - As of September 3, the fund's net asset value growth rate over the past three months was 16.30%, ranking 384 out of 607 comparable funds; over the past six months, it was 22.44%, ranking 237 out of 607; and over the past year, it was 25.69%, ranking 500 out of 604 [4]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 7.05 times, compared to the industry average of 33.74 times; the weighted average price-to-book (P/B) ratio was about 0.5 times, against an industry average of 2.47 times; and the weighted average price-to-sales (P/S) ratio was around 0.98 times, while the industry average was 2.07 times, indicating that all three valuation metrics are below the industry average [9]. Growth Metrics - For the first half of 2025, the weighted average year-on-year revenue growth rate (TTM) of the stocks held by the fund was 0.05%, and the weighted average net profit growth rate (TTM) was 0.03%, with a weighted annualized return on equity of 0.07% [15]. Fund Size and Shareholder Composition - As of June 30, 2025, the fund's total size was 49.2887 million yuan, with 839 holders collectively owning 46.5021 million shares. Management employees held 531,100 shares, accounting for 1.14%, while individual investors held 100% of the shares [31][34]. Trading Activity - The fund's turnover rate over the last six months was approximately 140.96%, which is consistently lower than the industry average [37].

Core Viewpoint - The AI Fund Oriental Innovation Medical Stock A (018045) reported a profit of 1.9706 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.109 yuan. The fund's net value growth rate was 12.88%, and the fund size reached 16.5886 million yuan by the end of the reporting period [2]. Fund Performance - As of September 3, 2025, the fund's net value growth rates were 32.62% over the past three months, 41.95% over the past six months, and 64.68% over the past year, ranking 13th, 27th, and 22nd respectively among comparable funds [5]. - The fund's maximum drawdown since inception was 28.85%, with the largest quarterly drawdown occurring in Q1 2024 at 23.3% [28]. Investment Strategy - The fund employs a combination of top-down industry analysis and bottom-up stock selection, focusing on innovative industry chains, pharmacies, consumer healthcare, and equipment upgrades while avoiding sectors in decline [2]. Fund Holdings and Valuation - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately -307.54, compared to the industry average of -135.64. The weighted average price-to-book (P/B) ratio was about 5, while the industry average was 4.24 [10]. - The fund's weighted average revenue growth rate for the first half of 2025 was 0.01%, and the weighted average net profit growth rate was 3.06% [16]. Fund Composition - As of June 30, 2025, the fund had a total of 642 holders, with individual investors holding 100% of the shares. The top ten holdings included companies such as Yuyuan Pharmaceutical, Maiwei Biotechnology, and Heng Rui Medicine [34][40]. - The fund's average stock position since inception was 73.6%, with a peak of 91.98% at the end of the first half of 2025 [31].

Core Viewpoint - The AI Fund, Hang Seng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), reported a profit of 5.1833 million yuan for the first half of 2025, with a weighted average profit per fund share of 0.1009 yuan. The fund's net value growth rate was 9.81%, and its total scale reached 56.6848 million yuan by the end of the first half of the year [2]. Fund Performance - As of September 3, the fund's unit net value was 1.354 yuan. The fund manager, Xing Cheng, oversees four funds, with the highest one-year return of 83.54% for Hang Seng Qianhai High-end Manufacturing Mixed A, while the lowest was 40.53% for Hang Seng Qianhai Hong Kong Stock Connect Selected Mixed [2]. - The fund's recent performance includes a three-month net value growth rate of 24.31%, a six-month growth rate of 24.89%, a one-year growth rate of 42.72%, and a three-year growth rate of -24.70% [5]. Valuation Metrics - As of June 30, 2025, the fund's weighted price-to-earnings (P/E) ratio was approximately 21.41 times, compared to the industry average of 25.34 times. The weighted price-to-book (P/B) ratio was about 2.82 times, while the industry average was 2.34 times. The weighted price-to-sales (P/S) ratio was around 2.11 times, slightly above the industry average of 2.09 times [10]. Growth Metrics - For the first half of 2025, the fund's weighted revenue growth rate was 0.23%, and the weighted net profit growth rate was 0.84%. The weighted annualized return on equity was 0.13% [17]. Risk and Return Metrics - The fund's Sharpe ratio over the past three years was -0.4274, ranking 284 out of 319 comparable funds. The maximum drawdown over the same period was 50.54%, with the largest quarterly drawdown occurring in Q1 2024 at 29.78% [26][28]. - The fund maintained an average stock position of 89.57% over the past three years, with a peak of 94.03% at the end of Q1 2025 and a low of 69.98% at the end of 2022 [31]. Fundholder Composition - As of June 30, 2025, the fund had 2,888 holders, collectively holding 49.8427 million shares. Institutional investors held 64.60% of the shares, while individual investors accounted for 35.40% [36]. Trading Activity - The fund's turnover rate for the last six months was approximately 112.67% [39]. Top Holdings - As of June 30, 2025, the fund's top ten holdings included Shenghong Technology, Dongpeng Beverage, Lanke Technology, Chuangfeng Power, New Strong Link, Daotong Technology, Pudong Development Bank, Longxin General, Daikin Heavy Industry, and Haoyuan Pharmaceutical [42].

Core Viewpoint - The AI Fund,招商丰利灵活配置混合基金A, reported a profit of 1.6851 million yuan for the first half of 2025, with a net asset value growth rate of 8.33% [2]. Fund Performance - As of September 3, 2025, the fund's unit net value was 1.566 yuan, with a one-year return of 54.59%, ranking it 207 out of 880 comparable funds [2][5]. - The fund's performance over the last three months showed a growth rate of 13.40%, ranking 586 out of 880, and over the last six months, it was 17.57%, ranking 409 out of 880 [5]. Fund Management Outlook - The fund manager expressed optimism for the second half of 2025, despite potential extreme changes in the internal and external environment, emphasizing the importance of holding companies with long-term competitive advantages [2]. - The fund plans to maintain a high position and balanced layout, focusing on globally competitive Chinese companies in technology, manufacturing, consumption, and overseas expansion [2]. Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 53.78, significantly higher than the industry average of 15.75 [10]. - The weighted average price-to-book (P/B) ratio was about 2.93, compared to the industry average of 2.52, and the weighted average price-to-sales (P/S) ratio was 2.71, against an industry average of 2.16 [10]. Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.01%, while the weighted average net profit growth rate was -0.22% [18]. Fund Composition - As of June 30, 2025, the fund had a total scale of 20.7879 million yuan, with 1,042 holders owning a total of 14.5406 million units [32][35]. - The top ten holdings included companies such as赛轮轮胎,金诚信, and普源精电 [40]. Trading Activity - The fund's turnover rate for the last six months was approximately 187.82%, which has been below the industry average for two consecutive years [38].